Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Expands fermentation capacities by almost 2,000 cubic meters and adds additional capacities for recovery and purification processes.
May 11, 2023
By: Anthony Vecchione
The Wacker Chemical Group has acquired contract manufacturing organization (CMO) ADL BioPharma for approximately €100 million. The shares were purchased from Kartesia, a financial investor with whom Wacker signed a corresponding agreement finalizing the transaction last week. Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The acquisition of the company, employing a staff of roughly 300, expands Wacker’s fermentation capacities by almost 2,000 cubic meters (gross volume) and adds additional capacities for recovery and purification processes. Wacker said that it will continue and grow existing customer relationships maintained by ADL BioPharma in its capacity as CMO for fermentation-based products for the food, pharmaceutical and consumer goods industries. “Acquiring ADL BioPharma is an important step in the continued growth of our biotechnology business, with which we expect to generate one billion euros in sales in 2030,” said Wacker’s CEO Christian Hartel, explaining the reasons for the investment. “Development at ADL BioPharma has been very good in recent years, and their sales have grown considerably. The additional fermentation capacities will provide a foundation for growth in the field of sustainably produced dietary ingredients. Wacker’s technological expertise combined with the capacities of ADL BioPharma will make us a much stronger player on this growth market.” The acquisition of ADL BioPharma now makes Wacker owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters (gross volume). Susanne Leonhartsberger, head of the Wacker Biosolutions business division, said, “ADL BioPharma’s CMO business is a very good fit for our portfolio. The company maintains extensive, extraordinarily important customer relationships that we will continue to pursue and expand still further. We will integrate these activities into Wacker Biosolutions, for example through the production of sustainable ingredients for the foods and nutritional supplements industries. This is an area where we foresee opportunities for growth at the León site in the coming years. We are happy to welcome our new colleagues into the company and plan to work with them on the continuous expansion of our business.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !